Scarica l'app Stockscreener
16.85
2.25%
0.37
Dopo l'orario di chiusura:
16.50
-0.35
-2.08%
Precedente Chiudi:
$16.48
Aprire:
$16.48
Volume 24 ore:
419.64K
Relative Volume:
0.36
Capitalizzazione di mercato:
$527.24M
Reddito:
-
Utile/perdita netta:
$-69.47M
Rapporto P/E:
-3.0104
EPS:
-5.5973
Flusso di cassa netto:
$-73.92M
1 W Prestazione:
+4.53%
1M Prestazione:
-36.94%
6M Prestazione:
-48.20%
1 anno Prestazione:
-38.19%
Intervallo 1D:
$16.05
$16.90
Intervallo di 1 settimana:
$15.36
$16.90
Portata 52W:
$15.36
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Nome
Lenz Therapeutics Inc
Settore
Industria
Telefono
858-925-7000
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Confronta LENZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
16.85 | 515.66M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2025-03-18 | Iniziato | TD Cowen | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-04-10 | Iniziato | Citigroup | Buy |
| 2024-03-27 | Iniziato | Piper Sandler | Overweight |
| 2023-02-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-14 | Iniziato | BTIG Research | Buy |
| 2022-03-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Iniziato | Morgan Stanley | Overweight |
| 2021-07-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ ... - Bluefield Daily Telegraph
Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East - Yahoo Finance
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ in the Middle East - marketscreener.com
LENZ Therapeutics and Lunatus Ink Exclusive Commercialization Partnership for VIZZ in Middle East - VisionMonday.com
Lenz Therapeutics and Lunatus announce partnership for Vizz(TM) - marketscreener.com
FDA-approved presbyopia eye drop VIZZ to reach Middle East - Stock Titan
LENZ Therapeutics responds to FDA adverse event report - MSN
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year LowWhat's Next? - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - PR Newswire
Is LENZ Therapeutics Inc a good long term investmentConsumer Goods Stocks & Free Stay Informed With Forecasts - earlytimes.in
Aug Mood: Why LENZ Therapeutics Inc stock is recommended by analystsQuarterly Profit Summary & Expert Approved Trade Ideas - moha.gov.vn
LENZ Therapeutics (LENZ) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.1%Time to Sell? - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
How LENZ Therapeutics Inc. stock compares to industry benchmarksPortfolio Growth Summary & Growth Focused Investment Plans - Улправда
Is LENZ Therapeutics Inc. stock trading near support levels2025 Institutional Moves & Technical Pattern Recognition Alerts - ulpravda.ru
Why LENZ Therapeutics Inc. stock could outperform in 2025Weekly Trade Analysis & Low Drawdown Investment Ideas - DonanımHaber
How sustainable is LENZ Therapeutics Inc. stock dividend payout2025 Biggest Moves & Technical Entry and Exit Tips - DonanımHaber
Why LENZ Therapeutics Inc. stock is popular among millennialsEarnings Overview Report & Free Weekly Watchlist of Top Performers - Улправда
Hedge Fund Bets: Why LENZ Therapeutics Inc. stock is popular among millennials2025 Analyst Calls & Weekly Setup with High ROI Potential - Улправда
LENZ Therapeutics Stock Plummets 42% With 10-Day Losing Streak - Trefis
LENZ Therapeutics (NASDAQ:LENZ) Shares Up 5%What's Next? - MarketBeat
LENZ Therapeutics: Was That A Market Overreaction? (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
LENZ Therapeutics Stock 9-Day Losing Spree: Stock Falls 40% - Trefis
LENZ Therapeutics Currently Down Nine Consecutive Days, On Pace for Longest Losing Streak Since March 2022 -- Data Talk - 富途牛牛
8-Day Sell-Off Sends LENZ Therapeutics Stock Down 39% - Trefis
LENZ Therapeutics (NASDAQ:LENZ) Shares Gap UpHere's What Happened - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Sees Large Volume IncreaseShould You Buy? - MarketBeat
LENZ Therapeutics Responds to FDA Adverse Event Report - TipRanks
LENZ Therapeutics Addresses Adverse Event Report - TradingView — Track All Markets
Lenz Therapeutics (Nasdaq: LENZ) provides update on VIZZ safety data report - Stock Titan
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report - GuruFocus
LENZ stock tumbles after retinal tear case surfaces in FDA database - Investing.com
LENZ stock plunges after adverse event report (LENZ:NASDAQ) - Seeking Alpha
Stempoint Capital LP Buys Shares of 183,912 LENZ Therapeutics, Inc. $LENZ - MarketBeat
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
LENZ Therapeutics (LENZ) Receives a Buy from Citi - The Globe and Mail
Stock Analysis: Will LENZ Therapeutics Inc stock rally after Fed decisionsWeekly Investment Summary & Long-Term Safe Investment Ideas - BỘ NỘI VỤ
Saturn V Capital Management LP Invests $10.03 Million in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Will LENZ Therapeutics Inc. stock gain from strong economyJuly 2025 Highlights & Smart Swing Trading Alerts - Newser
Transcript : LENZ Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Lenz Therapeutics: A Close Look (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 6.1%Here's What Happened - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires New Stake in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Geode Capital Management LLC Grows Stock Position in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ - Ophthalmology Times
Piper Sandler 37th Annual Healthcare Conference - LENZ Therapeutics
Leadership: Lenz Therapeutics CEO gives people autonomy and responsibility - MSN
Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea - marketscreener.com
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia - The Manila Times
Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):